Jessica Pougoue Ketchemen

Dr. Jessica Pougoue Ketchemen

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
ATAnjong Florence Tikum
Anjong Florence Tikum
ANAnand Krishnan Nambisan
Anand Krishnan Nambisan
JKJessica Pougoue Ketchemen
Jessica Pougoue Ketchemen
HBHanan Babeker
Hanan Babeker
MKMusharraf N. Khan
Musharraf N. Khan
HFHumphrey fonge
Humphrey fonge
Matuzumab and nimotuzumab are anti-EGFR monoclonal antibodies that bind to different epitopes of domain III of EGFR. We developed 89Zr-matuzumab as a PET probe for diagnosis/monitoring of response to treatment of a noncompeting anti-EGFR nimotuzumab antibody drug conjugate (ADC) using mouse colorectal cancer (CRC) xenografts. We developed 89Zr-matuzumab and performed quality control in EGFR-positive DLD-1 cells. The KD of matuzumab, DFO-matuzumab and 89Zr-matuzumab in DLD-1 cells was 5.9, 6.2 and 3 nM, respectively. A competitive radioligand binding assay showed that 89Zr-matuzumab and nimotuzumab bound to noncompeting epitopes of EGFR. MicroPET/CT imaging and biodistribution of 89Zr-matuzumab in mice bearing EGFR-positive xenografts (HT29, DLD-1 and MDA-MB-231) showed high uptake that was blocked with pre-dosing with matuzumab but not with the noncompeting binder nimotuzumab. We evaluated nimotuzumab-PEG6-DM1 ADC in CRC cells. IC50 of nimotuzumab-PEG6-DM1 in SNU-C2B, DLD-1 and SW620 cells was dependent on EGFR density and was up to five-fold lower than that of naked nimotuzumab. Mice bearing the SNU-C2B xenograft were treated using three 15 mg/kg doses of nimotuzumab-PEG6-DM1, and 89Zr-matuzumab microPET/CT was used to monitor the response to treatment. Treatment resulted in complete remission of the SNU-C2B tumor in 2/3 mice. Matuzumab and nimotuzumab are noncompeting and can be used simultaneously.

13 December 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
JKJessica Pougoue Ketchemen
Jessica Pougoue Ketchemen
FNFabrice Ngoh Njotu
Fabrice Ngoh Njotu
HBHanan Babeker
Hanan Babeker
AMAlissar Monzer
Alissar Monzer
ENEmmanuel Nwangele
Emmanuel Nwangele
HFHumphrey fonge
Humphrey fonge
Purpose: There is overwhelming interest to use actinium-225 ([225Ac]Ac) to develop targeted α therapies. Antibody–drug conjugates (ADC) are highly cytotoxic. Combining [225Ac]Ac with an ADC to develop an antibody–drug radioconjugate [225Ac]Ac–macropa–trastuzumab(T)–PEG6–emtansine (DM1), is expected to be more effective than its ADC (T–PEG6–DM1) against breast cancer. Experimental Design: [89Zr]Zr–p-isothiocyanatobenzyl desferrioxamine (DFO)–T–PEG6–DM1 (imaging) and [225Ac]Ac–macropa–T–PEG6–DM1 (radiotherapy) were developed. Biodistribution and safety evaluations of [225Ac]Ac–macropa–T-PEG6–DM1 were carried out in non–tumor-bearing BALB/c mice. MicroPET imaging and biodistribution were done using [89Zr]Zr-DFO–T–PEG6–DM1, and radiotherapy using [225Ac]Ac–macropa–T–PEG6–DM1 was carried out in athymic BALB/c nude mice bearing trastuzumab-resistant HCC1954 and trastuzumab-DM1 (T-DM1)/trastuzumab-resistant JIMT-1 tumor-bearing mice. Results: After 7 days of incubation at 37°C, [225Ac]Ac–macropa–T–PEG6–DM1 was stable in both human serum (89.2% ± 0.9%) and PBS (82.8% ± 0.4%). T–PEG6–DM1 (8 mg/kg) and [225Ac]Ac–macropa–T–PEG6–DM1 (3 × 18 kBq) administered separately in non–tumor-bearing mice 10 days apart were well tolerated biochemically and hematologically. Imaging and biodistribution showed high tumor uptake of [89Zr]Zr-DFO–T–PEG6–DM1 in tumor-bearing mice at 120 hours after injection: 38.1% ± 2.8% IA/g (HCC1954) and 14.6% ± 1% IA/g (JIMT-1). In HCC1954 tumor-bearing mice, all treatment groups had complete remission (8/8), indicative of the responsiveness of the xenograft to T-DM1–based treatments, whereas for JIMT-1 xenografts (having 1/8 complete remission) at 23 days after treatment, tumor volumes were 332.1 ± 77.5 vs. 244.6 ± 63 vs. 417.9 ± 62.1 vs. 102.4 ± 18.5 for the saline (negative control), T-DM1 (positive control), T–PEG6–DM1, and [225Ac]Ac–macropa–T–PEG6–DM1, respectively. Conclusions: [225Ac]Ac–macropa–T–PEG6–DM1 is more potent than ADC against trastuzumab-resistant breast cancer and necessitates clinical translation.

16 December 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
HBHanan Babeker
Hanan Babeker
JKJessica Pougoue Ketchemen
Jessica Pougoue Ketchemen
ASArunkumar Annan Sudarsan
Arunkumar Annan Sudarsan
SASamitha Andrahennadi
Samitha Andrahennadi
ATAnjong Florence Tikum
Anjong Florence Tikum
MUMaruti Uppalapati
Maruti Uppalapati
Antibodies that recognize cancer biomarkers, such as MUC16, can be used as vehicles to deliver contrast agents (imaging) or cytotoxic payloads (therapy) to the site of tumors. MUC16 is overexpressed in 80% of epithelial ovarian cancer (EOC) and 65% of pancreatic ductal adenocarcinomas (PDAC), where effective ‘theranostic’ probes are much needed. This work aims to develop fully human antibodies against MUC16 and evaluate them as potential immuno-PET imaging probes for detecting ovarian and pancreatic cancers. We developed a fully human monoclonal antibody, M16Ab, against MUC16 using phage display. M16Ab was conjugated with p-SCN-Bn-DFO and radiolabeled with 89Zr. 89Zr-DFO-M16Ab was then evaluated for binding specificity and affinity using flow cytometry. In vivo evaluation of 89Zr-DFO-M16Ab was performed by microPET/CT imaging at different time points at 24–120 h post injection (p.i.) and ex vivo biodistribution studies in mice bearing MUC16-expressing OVCAR3, SKOV3 (ovarian) and SW1990 (pancreatic) xenografts. 89Zr-DFO-M16Ab bound specifically to MUC16-expressing cancer cells with an EC50 of 10nM. 89Zr-DFO-M16Ab was stable in serum and showed specific uptake and retention in tumor xenografts even after 120 h p.i. (microPET/CT) with tumor-to-blood ratios > 43 for the SW1990 xenograft. Specific tumor uptake was observed for SW1990/OVCAR3 xenografts but not in MUC16-negative SKOV3 xenografts. Pharmacokinetic study shows a relatively short distribution (t1/2α) and elimination half-life (t1/2ß) of 4.4 h and 99 h, respectively. In summary, 89Zr-DFO-M16Ab is an effective non-invasive imaging probe for ovarian and pancreatic cancers and shows promise for further development of theranostic radiopharmaceuticals.

24 March 2025 in Cancer Research
Verified
Journal Article
Closed access
ATAnjong Florence Tikum
Anjong Florence Tikum
NHNikita W. Henning
Nikita W. Henning
JKJessica Pougoue Ketchemen
Jessica Pougoue Ketchemen
ADAlireza Doroudi
Alireza Doroudi
HBHanan Babeker
Hanan Babeker
HFHumphrey fonge
Humphrey fonge
EGFR is expressed in approximately 80% to 85% of colorectal cancers. Although anti-EGFR antibodies benefit some patients with colorectal cancer, tumors with Kirsten rat sarcoma viral oncogene (KRAS) or B-rapidly accelerated fibrosarcoma (BRAF), a proto-oncogene serine/threonine protein kinase, mutations are resistant. In this study, we developed a theranostic approach that uses an anti-EGFR antibody–drug conjugate labeled with either [225Ac]Ac or [89Zr]Zr and evaluated the strategy against KRAS- and BRAF-mutant EGFR-positive colorectal cancer models. The antibody–drug radioconjugate [225Ac]Ac-macropa-nimotuzumab-PEG6-DM1 showed enhanced in vitro cytotoxicity compared with the unlabeled antibody–drug conjugate nimotuzumab-PEG6-DM1. [225Ac]Ac-macropa-nimotuzumab-PEG6-DM1 extended the survival of mice bearing all tested xenografts compared with untreated and nimotuzumab-PEG6-DM1–treated controls. For the BRAFV600E-mutant xenograft, the median survival was not reached following treatment with [225Ac]Ac-macropa-nimotuzumab-PEG6-DM1, whereas it was 24.5 and 39 days for the saline-treated and nimotuzumab-PEG6-DM1–treated groups, respectively. Micro-PET/CT imaging using the nonoverlapping anti-EGFR radioimmunoconjugate [89Zr]Zr-DFO-matuzumab before and after treatment of orthotopic colorectal cancer xenografts showed that 1/5 mice in the treatment group had complete remission, whereas metastatic spread was prevented in the other mice (4/5). These results show that treatment with [225Ac]Ac-macropa-nimotuzumab-PEG6-DM1 is a potential therapeutic approach for KRAS- and BRAFV600E-mutant metastatic colorectal cancer. Significance: Radiolabeling with [225Ac]Ac improves the efficacy of an anti-EGFR antibody-drug conjugate in KRAS- and BRAFV600E-mutant colorectal cancer, providing hope for patients with these mutations who do not qualify for EGFR-targeted therapies.

22 April 2025 in Biomolecules
Verified
Journal Article
Open access
PDF file
OBOlga Bednova
Olga Bednova
JKJessica Pougoue Ketchemen
Jessica Pougoue Ketchemen
HMHazem Mslati
Hazem Mslati
MBMark Barok
Mark Barok
HJHeikki Joensuu
Heikki Joensuu
JLJeffrey Victor Leyton
Jeffrey Victor Leyton
Antibody-based agents have become a preferred treatment for various diseases, including cancer, due to significant advances in antibody engineering. The use of single-chain Fv-Fcs (scFv-Fcs) has been a promising engineering approach for therapeutic design. The concept is that the Fc provides increased stability and target binding and ultimately improves performance. However, the structural and dynamic relationship between the variable and Fc domains, which are fused in close proximity, and the impact on stability and target binding are not well understood. This study evaluated trastuzumab-derived scFv-Fc antibodies, focusing on the impact of their design on important biopharmaceutical parameters. Computational modelling and molecular dynamics, alongside experimental studies, were used to ascertain their dynamics, expression and purification, stabilities, and binding potencies. The results showed that the scFv subunits exhibited stochastic interplays that lead to diverse shapes and were associated with functional performance. This new understanding of scFv-Fc antibodies and their structural and functional nuances provides important details to further guide the design of more effective and less toxic therapeutics.

22 December 2025 in EJNMMI Radiopharmacy and Chemistry
Verified
Journal Article
Open access
JKJessica Pougoue Ketchemen
Jessica Pougoue Ketchemen
SAStephen Ahenkorah
Stephen Ahenkorah
ENEmmanuel Nwangele
Emmanuel Nwangele
SMSiphelele Siphesihle Pearl Malaza
Siphelele Siphesihle Pearl Malaza
MOMaarten Ooms
Maarten Ooms
HFHumphrey fonge
Humphrey fonge
Background: Actinium-225 ( 225 Ac) based targeted alpha therapies (TAT) have emerged as a promising strategy for the treatment of several cancer types due to its favourable decay properties, including high linear energy transfer and short particle range, which enable precise tumour targeting. However, there are limited bifunctional chelators (BFCs) available for 225 Ac. In this study, we aim to evaluate the potential of DEPA-based chelators for 225 Ac-labelling. Results: The BFCs 3p- C -DEPA- NO2 , 3p- C -DEPA- NCS , and 3p- C -DEPA -TFP -PEG 4 were synthesized with high yield (≥ 86%) and purity (> 96%). Excellent radiochemical conversions (RCCs) were achieved for [ 225 Ac]Ac-3p- C -DEPA- NO2 across a range of concentrations (0.7- 13.4 µg) with high RCC’s (93.7 to 96.8%) after 1 h at room temperature. Stability studies demonstrated that over 95% of this 225 Ac-labelled complex remained intact after 6 days in human serum. The HPLC and bioanalyzer analysis of the immunoconjugates 3p- C -DEPA -TFP -PEG 4 -trastuzumab, DOTA-trastuzumab, 3p- C -DEPA-trastuzumab and macropa-trastuzumab showed 98% purity with less than 2% impurities. A RCC of 94.6% was obtained for [ 225 Ac]Ac-3p- C -DEPA-trastuzumab, 93.5% for [ 225 Ac]Ac-3p- C -DEPA -TFP -PEG 4 -trastuzumab, 80.9% for [ 225 Ac]Ac-DOTA-trastuzumab, and 96.5% for [ 225 Ac]Ac-macropa-trastuzumab after 2 h incubation at 37 °C. In PBS, high stability of [ 225 Ac]Ac-3p- C -DEPA -TFP -PEG 4 -trastuzumab was observed (91.3 ± 4.3%), which is comparable to that of [ 225 Ac]Ac-macropa-trastuzumab (81.9 ± 5.6%). In contrast, [ 225 Ac]Ac-3p- C -DEPA-trastuzumab and [ 225 Ac]Ac-DOTA-trastuzumab were less stable in PBS with only 48.3 ± 1.2% and 60.1 ± 0.6% intact tracer left after 10 d. There were no major significant differences between the biodistribution profile of [ 225 Ac]Ac-3p-C-DEPA-trastuzumab, [ 225 Ac]Ac-3p- C -DEPA -TFP -PEG 4 -trastuzumab, [ 225 Ac]Ac-DOTA-trastuzumab and [ 225 Ac]Ac-macropa-trastuzumab in all organs of interest ( p > 0.05 for all organs). Conclusions: 3p- C -DEPA -TFP -PEG₄ demonstrated excellent potential as a bifunctional chelator for 225 Ac, showing high radiolabelling efficiency under mild conditions and outstanding in vitro stability of the resulting 225 Ac-labelled bioconjugate. Further preclinical studies are warranted to validate its therapeutic potential.